Adverse Event Profile in Advance Hepatocellular Carcinoma treated with Sorafenib Presenting to CMH Rawalpindi

Authors

  • Masaba Masood Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Nadeem Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Aamira Ali Department of Medical Oncology, POF Hospital Wah Cantt, Pakistan
  • Tahir Manzoor Lone Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Amjad Khan Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Assam Ahmad Department of Medical Oncology, THQ Hospital, Baffa, Mansehra Pakistan

DOI:

https://doi.org/10.51253/pafmj.v73i4.7889

Keywords:

Adverse effects, Hepatocellular carcinoma, Sorafenib

Abstract

 

Objective: To look for adverse event profiles in advance of hepatocellular carcinoma treated with Sorafenib presenting to CMH Rawalpindi and study associated socio-demographic factors

Study Design: Comparative cross-sectional study

Place and Duration of Study: Oncology Department, Combined Military Hospital, Rawalpindi Pakistan, from Dec 2020 to Nov 2021.

Methodology: Three hundred patients with diagnosed hepatocellular carcinoma in advanced stage taking Sorafenib chemotherapy for more than three months and less than one year were included in the study. Each patient was assessed for relevant adverse effects in the follow-up outpatient visits by a consultant oncologist.

Results: Out of 300 cancer patients using Sorafenib for more than three months and less than one year, 212(70.7%) patients had at least one or more adverse effects, while 88(29.3%) did not experience any adverse effects. Diarrhoea 120(40%) was the most common adverse effect, followed by rash/desquamation 110(36.7%). Advancing age was statistically significantly associated (p-value-0.001) with adverse effects among the target population.

Conclusion: A significant number of patients suffering from hepatocellular carcinoma using Sorafenib had mild to moderate adverse effects. Physicians should keep an eye on patients with advancing age for adverse effects of this medication.

Downloads

Download data is not yet available.

Downloads

Published

31-08-2023

Issue

Section

Original Articles

How to Cite

1.
Masood M, Nadeem M, Ali A, Lone TM, Khan A, Ahmad A. Adverse Event Profile in Advance Hepatocellular Carcinoma treated with Sorafenib Presenting to CMH Rawalpindi. Pak Armed Forces Med J [Internet]. 2023 Aug. 31 [cited 2024 Jun. 14];73(4):1071-4. Available from: https://pafmj.org/PAFMJ/article/view/7889